Lytix Biopharma (LYTIX) Q4 2025 earnings summary

Executive summary

• Entered a decisive new phase with strong clinical data for ruxotemitide (LTX-315) and LTX-401, supported by positive interim NeoLIPA results and expanded strategic opportunities.

• External commercial assessments position ruxotemitide and LTX-401 as potential blockbusters across multiple oncology indications.

• Partnership with Verrica Pharmaceuticals advanced, with preparations for pivotal Phase III in basal cell carcinoma and additional immune-response data reinforcing ruxotemitide's profile.

• Raised NOK 77.3 million in January 2026, strengthening the balance sheet and supporting execution of key milestones.

• Leadership and board enhanced to support late-stage execution and commercial readiness.

Financial highlights

• Q4 2025 operating expenses were NOK 21.2 million, down from NOK 33 million in Q4 2024, mainly due to reduced R&D activity.

• Cash and short-term investments at Q4 2025 totaled NOK 72 million, providing a solid runway into 2026.

• Loss for Q4 2025 was NOK 18.7 million, improved from NOK 31.9 million in Q4 2024.

• Other operating expenses increased to NOK 5.5 million, reflecting organizational strengthening and investment in business development.

• Cash flow from operations was negative NOK 29.5 million in H2 2025, an improvement from negative NOK 33.1 million in H2 2024.

Outlook and guidance

• Strategic priority for 2026 is to advance ruxotemitide into pivotal clinical development and commercialization, with clearly defined regulatory pathways.

• NeoLIPA topline results expected in H2 2026; pivotal study for ruxotemitide in preparation.

• LTX-401 clinical entry targeted for 2027, with ongoing evaluation of strategic development opportunities.

• Focus remains on progressing ruxotemitide in neoadjuvant melanoma and engaging in partnering discussions.

• Expectation of continued disciplined execution, targeted investment, and strategic collaboration.